Literature DB >> 21715707

Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis.

D Strbian1, T Sairanen, A Meretoja, J Pitkäniemi, J Putaala, O Salonen, H Silvennoinen, M Kaste, T Tatlisumak.   

Abstract

OBJECTIVES: To assess the impact of symptomatic intracerebral hemorrhage (sICH) on outcome of thrombolysis-treated ischemic stroke patients, as additional to recognized prognosticators.
METHODS: The study cohort included 985 ischemic stroke patients treated with IV thrombolysis at the Helsinki University Central Hospital (1995-2008). In a multivariable model adjusted for baseline stroke severity, age, onset-to-treatment time, baseline glucose, hyperdense cerebral artery sign, and early infarct signs on baseline imaging, and prior modified Rankin Scale (mRS), we calculated risk ratios (RRs) of patients with sICH (separately per Safe Implementation of Thrombolysis in Stroke[SITS]-Monitoring Study, European Cooperative Acute Stroke Study II [ECASS-II], and National Institute of Neurological Disorders and Stroke [NINDS] definitions) for poor 3-month outcome (mRS 3-6) and mortality. Receiver operating characteristic (ROC) curve and integrated discrimination improvement (IDI) evaluated impact of sICH on outcome. Internal cross-validation of the model was done with bootstrap statistics.
RESULTS: The frequency of sICH was 2.1% (SITS), 7.0% (ECASS-II), and 9.4% (NINDS). RRs for poor and fatal outcome, respectively, were 1.7 and 4.8 (SITS), 1.6 and 3.8 (ECASS-II), and 1.6 and 3.4 (NINDS). In IDI analyses, sICH improved prediction model for 3-month mRS of 3-6 and 4-6, respectively, by 1.4% and 3.0% (SITS), 4.0% and 5.9% (ECASS-II), and 4.7% and 6.1% (NINDS). In case of 3-month mRS 5-6 and mortality, it was 6.1% and 5.3% (SITS), 11.3% and 9.3% (ECASS-II), and 10.3% and 8.0% (NINDS). ROC analysis revealed similar results.
CONCLUSIONS: Patients with sICH have increased risk of poor and fatal outcome. Compared with recognized stroke prognosticators, contribution of sICH is smaller. Definition-wise, ECASS-II- and NINDS-based sICH contribute relatively more; ECASS-II has the largest contribution to worst outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715707     DOI: 10.1212/WNL.0b013e3182267b8c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  45 in total

1.  Brain hemorrhage after endovascular reperfusion therapy of ischemic stroke: a threshold-finding whole-brain perfusion CT study.

Authors:  Arturo Renú; Carlos Laredo; Raúl Tudela; Xabier Urra; Antonio Lopez-Rueda; Laura Llull; Laura Oleaga; Sergio Amaro; Ángel Chamorro
Journal:  J Cereb Blood Flow Metab       Date:  2015-12-07       Impact factor: 6.200

2.  Computed Tomography Perfusion Derived Blood-Brain Barrier Permeability Does Not Yet Improve Prediction of Hemorrhagic Transformation.

Authors:  Alexander D Horsch; Edwin Bennink; Tom van Seeters; L Jaap Kappelle; Yolanda van der Graaf; Willem P T M Mali; Hugo W A M de Jong; Birgitta K Velthuis; Jan Willem Dankbaar
Journal:  Cerebrovasc Dis       Date:  2018-01-08       Impact factor: 2.762

3.  Predictors and clinical relevance of hemorrhagic transformation after endovascular therapy for anterior circulation large vessel occlusion strokes: a multicenter retrospective analysis of 1122 patients.

Authors:  Raul G Nogueira; Rishi Gupta; Tudor G Jovin; Elad I Levy; David S Liebeskind; Osama O Zaidat; Ansaar Rai; Joshua A Hirsch; Daniel P Hsu; Marilyn M Rymer; Ashis H Tayal; Ridwan Lin; Sabareesh K Natarajan; Ashish Nanda; Melissa Tian; Qing Hao; Junaid S Kalia; Michael Chen; Alex Abou-Chebl; Thanh N Nguyen; Albert J Yoo
Journal:  J Neurointerv Surg       Date:  2014-01-08       Impact factor: 5.836

4.  Progesterone in transient ischemic stroke: a dose-response study.

Authors:  Seema Yousuf; Fahim Atif; Iqbal Sayeed; Huiling Tang; Donald G Stein
Journal:  Psychopharmacology (Berl)       Date:  2014-04-22       Impact factor: 4.530

5.  Cerebellar vermis: a vulnerable location of remote brain haemorrhages after thrombolysis for ischaemic stroke.

Authors:  Herbert Tejada-Meza; Pedro J Modrego
Journal:  Neurol Sci       Date:  2016-10-05       Impact factor: 3.307

Review 6.  Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.

Authors:  Andrew M Southerland; Karen C Johnston
Journal:  Ann N Y Acad Sci       Date:  2012-09       Impact factor: 5.691

7.  Clotting factors to treat thrombolysis-related symptomatic intracranial hemorrhage in acute ischemic stroke.

Authors:  Yazan J Alderazi; Niravkumar V Barot; Hui Peng; Farhaan S Vahidy; Digvijaya D Navalkele; Navdeep Sangha; Vivek Misra; Sean I Savitz
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-12-08       Impact factor: 2.136

8.  Mortality in patients treated by intra-venous thrombolysis for ischaemic stroke.

Authors:  Loubna Majhadi; Didier Leys; Marie Bodenant; Hilde Hénon; Régis Bordet; Charlotte Cordonnier
Journal:  J Neurol       Date:  2013-02-07       Impact factor: 4.849

9.  Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.

Authors:  Neal M Rao; Steven R Levine; Jeffrey A Gornbein; Jeffrey L Saver
Journal:  Stroke       Date:  2014-08-05       Impact factor: 7.914

10.  Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes.

Authors:  Ilaria Maestrini; Daniel Strbian; Sophie Gautier; Elena Haapaniemi; Solène Moulin; Tiina Sairanen; Nelly Dequatre-Ponchelle; Gerli Sibolt; Charlotte Cordonnier; Susanna Melkas; Didier Leys; Turgut Tatlisumak; Régis Bordet
Journal:  Neurology       Date:  2015-09-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.